KRTL Holding Group Provides Corporate Update: SIGMA Integration, Regulatory Progress, and PCAOB Audit Engagement
- Anthony Hernandez
- Oct 22
- 4 min read
In the third quarter of 2025, KRTL Holding successfully closed its strategic merger with Industria Químico-Farmacéutica SIGMA Corp., a Bolivian pharmaceutical manufacturer with over 50 years of continuous operation and a national reputation for quality manufacturing, public health alignment, and product innovation. The deal was finalized in September 2025, and initial integration steps are in process within the first 30 days, including organizational realignment, catalog assessment, and operational audits. The integration of SIGMA under the KRTL Biotech Inc. subsidiary marks a major advancement in the Company’s long-term strategy to build a scalable, international life sciences platform.
"The SIGMA transaction positions KRTL to be more than a U.S. holding company — it makes us an operating force in international pharma," said Cesar Herrera, CEO of KRTL Holding Group Inc. "The acquisition added infrastructure, talent, and immediate product availability to KRTL’s business model."
In connection with this transaction, KRTL Biotech has already:
Introduced SIGMA's pharmaceutical and nutraceutical products to U.S. and LATAM audiences
Highlighted multiple therapeutic categories through a structured press campaign
Begun regulatory review of U.S. market entry pathways, including OTC Monograph and ANDA considerations
Laid the groundwork for revenue consolidation from SIGMA's operations
Additionally, the Company has continued to advance its regulatory transparency. In Q4 2025, KRTL Holding continues its internal review and content update process to align fully with SEC Rule 15c2-11.
"Regulatory clarity is not optional; it is central to our identity as a company," Herrera added. "We are taking the necessary steps to strengthen our reporting and to ensure shareholders and stakeholders have full insight into our financial and operational progress."
To further this mission, KRTL Holding has formally engaged an external firm to initiate its PCAOB-compliant audit. This audit marks a critical milestone toward potential uplisting initiatives and supports the Company's objective to broaden its access to institutional and strategic capital. This engagement signals KRTL's commitment to transparency, long-term governance, and sustainable growth.
"With SIGMA fully integrated and a PCAOB audit underway, KRTL is not just building products — we're building infrastructure, compliance, and value," Herrera concluded.
About KRTL Holding Group, Inc.
KRTL Holding Group, Inc. (OTC: KRTL) operates through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp. The Company leverages strategic synergies across biotech, technology, and emerging markets to drive growth and deliver shareholder value.
About KRTL Biotech, Inc.
KRTL Biotech, Inc., a 51% majority-owned subsidiary of KRTL Holding Group Inc. (OTC: KRTL), recently completed a merger with Industria Químico-Farmacéutica SIGMA Corp. S.R.L., integrating SIGMA’s decades of pharmaceutical expertise and infrastructure into KRTL’s international life sciences platform. This merger combines KRTL’s research, compliance, and global market access with SIGMA’s advanced Bolivian manufacturing capabilities, aligning both companies to deliver world-class pharmaceutical and nutraceutical solutions.
About Industria Químico Farmacéutica SIGMA Corp SRL
SIGMA is a Bolivian pharmaceutical manufacturer with more than five decades of experience in formulation, quality manufacturing, and commercialization of essential and complementary health products, including pharmaceuticals and nutraceuticals.
For more information:
Forward-Looking Statements
This press release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking statements” within the meaning of applicable securities legislation. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Words such as “anticipates,” “will,” “believes,” “plans,” “expects,” “intends,” “projects,” “estimates,” “future,” and “opportunity” and similar expressions are used to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments and acquisitions; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company. Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law.
Comments